Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

The New England Journal of Medicine
Bernard ZinmanEMPA-REG OUTCOME Investigators


The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the pooled empagliflozin group versus the placebo group. The key secondary composite outcome was the primary outcome plus hospitalization for unstable angina. A total of 7020 patients were treated (median observation time, 3.1 years). The primary outcome occurred in 490 of 4687 patients (10.5%) in the pooled empagliflozin group and in 282 of 2333 patients (12.1%) in the placebo group (hazard ratio in the empagliflozin group, 0.86; 95.02% confidence interval, 0.74 to 0.99; P=0.04 for superiority). There were no significant between-group differences in the rates of myocardial infarction or stroke, but in the empagliflozin group there were significantly lower rates of death from cardiovascular causes (3.7%, vs. 5.9% in the placebo group; 38% relative risk reduction), hospitalization...Continue Reading

Associated Clinical Trials


May 22, 2002·JAMA : the Journal of the American Medical Association·Joshua A BeckmanPeter Libby
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Dec 29, 2009·European Heart Journal·Claudio RoncoUNKNOWN Acute Dialysis Quality Initiative (ADQI) consensus group
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Feb 22, 2014·Diabetes Care·George L Bakris, Mark Molitch
Apr 12, 2014·Diabetes Care·Hans-Ulrich HäringUNKNOWN EMPA-REG MET Trial Investigators
Jun 21, 2014·The Lancet. Diabetes & Endocrinology·Martin RidderstråleUNKNOWN EMPA-REG H2H-SU trial investigators
Oct 2, 2014·Diabetes Care·Ilkka TikkanenUNKNOWN EMPA-REG BP Investigators
Jan 16, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Silvio E InzucchiOdd Erik Johansen
Jan 27, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Linda A GalloVolker Vallon
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Jul 8, 2015·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh

❮ Previous
Next ❯


Nov 30, 2016·Hemodialysis International·Tushar Chopra, Mitchell H Rosner
Feb 17, 2017·Cardiovascular Research·Christoph Maack, Elizabeth Murphy
Feb 25, 2017·Der Internist·D Müller-Wieland, N Marx
Dec 13, 2016·Nature Reviews. Nephrology·Ralph A DeFronzoMuhammad Abdul-Ghani
Feb 14, 2017·Journal of Diabetes Research·M C Perez-MatosC O Mendivil
Jan 17, 2017·Internal Medicine·Junichiro AdachiChisato Maki
Dec 7, 2016·Journal of Cardiovascular Medicine·Adriano MurroneClaudio Cavallini
Mar 18, 2017·Molecular and Cellular Biochemistry·Adrian QuanSubodh Verma
Feb 9, 2017·Cardiovascular Research·Cher-Rin ChongEylem Levelt
Mar 17, 2017·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Atsushi Tanaka, Koichi Node
Jan 20, 2017·Current Diabetes Reports·Joseph M Pappachan, Ananth K Viswanath
May 26, 2017·Journal of Diabetes·Abigail E DoveKelly L Close
Jun 21, 2017·Trends in Endocrinology and Metabolism : TEM·Stanley S SchwartzMary E Herman
Jun 18, 2017·Nature Reviews. Endocrinology·Guillermo E Umpierrez
Mar 16, 2017·Diabetes, Obesity & Metabolism·Daniël H van Raalte, C Bruce Verchere
Jul 4, 2017·Expert Opinion on Pharmacotherapy·Alexandra Sophie MossGregory Y H Lip
Mar 24, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Ildiko Lingvay
Jul 8, 2017·Expert Opinion on Pharmacotherapy·Niki KatsikiDimitri P Mikhailidis
Feb 17, 2017·Therapeutic Advances in Endocrinology and Metabolism·Vasileios AndrianesisJohn Doupis
Nov 8, 2016·Expert Opinion on Drug Metabolism & Toxicology·Brian TomlinsonZhong-Min Liu
May 10, 2017·Clinical Pharmacology and Therapeutics·E LioudakiE S Ganotakis
Jul 6, 2017·Expert Opinion on Drug Safety·Marc S Rendell
Dec 10, 2016·Journal of Diabetes Science and Technology·Rina KagawaKazuhiko Ohe
Jul 26, 2017·Critical Pathways in Cardiology·Sara Lee
Jun 26, 2017·Current Heart Failure Reports·Frederik H Verbrugge
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Apr 24, 2017·Postgraduate Medical Journal·Cyrus R KumanaBernard M Y Cheung
Nov 30, 2016·Journal of Neurology, Neurosurgery, and Psychiatry·Konstantinos P ImprialosAsterios I Karagiannis

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

The New England Journal of Medicine
Christoph WannerEMPA-REG OUTCOME Investigators
Stroke; a Journal of Cerebral Circulation
Bernard ZinmanEMPA-REG OUTCOME Investigators (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients)
The New England Journal of Medicine
Steven P MarsoLEADER Trial Investigators
© 2022 Meta ULC. All rights reserved